Drug Synergism
This graph shows the total number of publications written about "Drug Synergism" by people in the URMC Research Network by year, and whether "Drug Synergism" was a major or minor topic of these publication.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Pizzey RL, Marquis RE, Bradshaw DJ. Antimicrobial effects of o-cymen-5-ol and zinc, alone & in combination in simple solutions and toothpaste formulations. Int Dent J. 2011 Aug; 61 Suppl 3:33-40.
-
Tu Z, Hamalainen-Laanaya HK, Crispe IN, Orloff MS. Synergy between TLR3 and IL-18 promotes IFN-? dependent TRAIL expression in human liver NK cells. Cell Immunol. 2011; 271(2):286-91.
-
Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23; 116(26):5983-90.
-
Saiko P, Graser G, Giessrigl B, Lackner A, Grusch M, Krupitza G, Basu A, Sinha BN, Jayaprakash V, Jaeger W, Fritzer-Szekeres M, Szekeres T. A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochem Pharmacol. 2011 Jan 1; 81(1):50-9.
-
Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-?B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol. 2010 Oct; 151(1):70-83.
-
Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol. 2010 Apr; 47(2):133-42.
-
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 2010 Sep; 17(9):1381-91.
-
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010 Jun 3; 115(22):4478-87.
-
Gerotziafas GT, Dupont C, Spyropoulos AC, Hatmi M, Samama MM, Kiskinis D, Elalamy I. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost. 2009 Jul; 102(1):42-8.
-
Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther. 2009 May; 8(9):808-19.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
